X-Linked Retinitis Pigmentosa

Ophthalmology·MeSH: Retinal Degeneration

Prevalence

25.0 / 100K

Incidence

1.5 / 100K/yr

10 drugs in development·5 companies·7 clinical trials

Drug Pipeline by Phase

Phase 3(5)

Drug	Company
4D-125 IVT Injection	4D Molecular Therapeutics, Inc. (FDMT)
AAV5-hRKp.RPGR	Replimune Group, Inc. (REPL)
Control	Replimune Group, Inc. (REPL)
genetic	GH Research PLC (GHRS)
Genetic	Replimune Group, Inc. (REPL)

Phase 2(3)

Drug	Company
4D-125	4D Molecular Therapeutics, Inc. (FDMT)
agtc-501	APPLIED GENETIC TECHNOLOGIES CORP (AGTC)
rAAV2tYF-GRK1-hRPGRco	Replimune Group, Inc. (REPL)

Phase 2/Phase 3(2)

Drug	Company
nsr-rpgr	Nightstar Therapeutics plc (NITE)
xlrp product candidate	APPLIED GENETIC TECHNOLOGIES CORP (AGTC)

BioSniper tracks 10 drugs in development for X-Linked Retinitis Pigmentosa across 5 companies.

There are 7 clinical trials targeting X-Linked Retinitis Pigmentosa tracked by BioSniper.

The estimated prevalence of X-Linked Retinitis Pigmentosa is approximately 25.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.